Evaxion A EVAX
NASDAQ EVAX
$3.31 +0.03 (+0.91%)
At close: Aug 21, 2026 · 4:00 PM EDT

Evaxion A (EVAX) Net Income towards Common Stockholders (2020 - 2026)

Evaxion A's (EVAX) quarterly Net Income towards Common Stockholders came in at -$3.6 million in Q1 2026, down 129.68% YoY from $12.2 million in Q1 2025, and up 38.68% on a QoQ basis from -$5.9 million in Q4 2025.

Evaxion A (EVAX) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Evaxion A (EVAX) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$3.6 million in Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 129.68% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.8 million (up 26.85% YoY) and the FY2025 annual result came in at -$7.7 million, up 27.07% from the prior year.
  • Net Income towards Common Stockholders advanced to -$3.6 million in Q1 2026, from -$5.9 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $5.8 million in Q1 2022 to a low of -$6.9 million in Q4 2022.
  • A 5-year average of -$3.3 million and a median of -$4.8 million in 2022 frame the typical range for Net Income towards Common Stockholders.
  • The widest YoY moves for Net Income towards Common Stockholders: up 338.66% in 2025, down 232.33% in 2025.
  • Tracing EVAX's Net Income towards Common Stockholders over 5 years: stood at -$6.9 million in 2022, then soared by 34.18% to -$4.5 million in 2023, then increased by 19.77% to -$3.6 million in 2024, then sank by 63.08% to -$5.9 million in 2025, then soared by 38.68% to -$3.6 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$3.6 million (Q1 2026), -$5.9 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -782.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 237.01 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 164.49 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -174.37 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -13.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 81.49 Mn
10 Evaxion A 27.61 Mn 27.61 Mn - -3.63 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -3.63 Mn
Dec 31, 2025 -5.92 Mn
Sep 30, 2025 4.62 Mn
Jun 30, 2025 -4.83 Mn
Mar 31, 2025 -1.58 Mn
Dec 31, 2024 -3.63 Mn
Sep 30, 2024 -1.94 Mn
Jun 30, 2024 -6.20 Mn
Mar 31, 2024 1.19 Mn
Dec 31, 2023 -4.52 Mn
Sep 30, 2023 -5.68 Mn
Jun 30, 2023 -5.68 Mn
Mar 31, 2023 -6.24 Mn
Dec 31, 2022 -6.87 Mn
Sep 30, 2022 -5.74 Mn
Jun 30, 2022 -4.77 Mn
Mar 31, 2022 5.79 Mn
Dec 31, 2021 -8.37 Mn
Sep 30, 2021 16.16 Mn
Jun 30, 2021 -10.91 Mn